Nightingale has continued to lay the groundwork for future growth by announcing new research customers where we see the potential for greater commercial opportunities in the future. The news adds some visibility to our top-line growth projections and provides a rationale for a positive share price development. The main risk to growth remains the success in scaling up the won clinical accounts. Against this backdrop, we think the share valuation has become too forward-oriented (+76% since our March 8 report). We believe the risk/reward is unsatisfactory based on the current data and await further news from the company's customer base or a moderation in the valuation.